Tags: RCC
Perioperative Approaches to Kidney Cancer
Abstract: This article provides an overview of the perioperative treatment strategies available for renal cancer. A review of the literature via PubMed, ClinicalTrials.gov, the American […]
Highlights in Renal Cell Carcinoma From the Seventeenth International Kidney Cancer Symposium
Highlights in Renal Cell Carcinoma From the Seventeenth International Kidney Cancer Symposium A Review of Selected Presentations From the Seventeenth International Kidney Cancer Symposium • November […]
Contemporary Management of Advanced Renal Cell Carcinoma
Abstract: Kidney cancer is the eighth most commonly diagnosed cancer in the United States, and nearly one-third of patients have locally advanced or metastatic disease […]
Highlights in Kidney Cancer From the American Society of Clinical Oncology Genitourinary Cancers Symposium
Highlights in Kidney Cancer From the American Society of Clinical Oncology Genitourinary Cancers Symposium February 8-10, 2018 • San Francisco, California Atezolizumab Plus Bevacizumab Improves Progression-Free Survival […]
Hem/Onc News
Rucaparib Approved for Maintenance Treatment in Recurrent Ovarian Cancer On April 6, the US Food and Drug Administration (FDA) approved rucaparib (Rubraca, Clovis Oncology) for maintenance […]
Highlights in Kidney Cancer From the 2017 American Society of Clinical Oncology Annual Meeting
1From the 2017 American Society of Clinical Oncology Annual Meeting June 2-6, 2017 • Chicago, Illinois Adjuvant Pazopanib Does Not Extend Disease-Free Survival in Locally Advanced […]
VEGF Inhibitors in Renal Cell Carcinoma
Abstract: The arrival of targeted therapies—vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors—and programmed death 1 (PD-1) inhibitors has […]